---
title: "Terns Pharmaceuticals (TERN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TERN.US.md"
symbol: "TERN.US"
name: "Terns Pharmaceuticals"
industry: "Pharmaceuticals"
datetime: "2026-05-20T10:35:20.907Z"
locales:
  - [en](https://longbridge.com/en/quote/TERN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TERN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TERN.US.md)
---

# Terns Pharmaceuticals (TERN.US)

## Company Overview

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -63.52 | 224 | - | - | - |
| PB | 6.07 | 152 | 14.54 | 6.03 | 1.62 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-17T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 10% |
| Hold | 9 | 90% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 52.93 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TERN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TERN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TERN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TERN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**